

## About Us

Leveraging world-class partnerships and cross-disciplinary teams, we aim to eliminate cancer through:

- Effective prevention
- Improved diagnostics and treatments
- Fundamental insights in the biology of disease

## Citing the Cancer Center Support Grant (CCSG)

All publications, press releases, or other documents that cite results from CCSG-supported research must include acknowledgment of the grant and maintain compliance with NIH Public Access Policy. All manuscripts accepted for publication must be submitted to PubMed Central and be assigned a PMCID.

You can find [citation guidelines](#) on the Cancer Consortium website.



Award Number P30 CA01570

## A MESSAGE FROM THE DIRECTOR, DR. GARY GILLILAND



The Fred Hutch/University of Washington Cancer Consortium's Cancer Center Support Grant application received a rating in the "Exceptional" range. This score is the highest level that can be awarded by the NCI for these five-year, multimillion-dollar grants and reflects peer review from our colleagues from other cancer centers. We can be proud that our focus on cancer has placed us among the nation's leaders.

**A TIME FOR TRANSITION:** Dr. Gary Gilliland, President and Director of Fred Hutchinson Cancer Research Center, has announced his plans to step down after five years of service.

[Read more here](#)

## SUBMITTING A MANUSCRIPT? PLEASE CITE THE CCSG!



On behalf of Cancer Consortium Director, Dr. Gary Gilliland, we kindly remind you to acknowledge the CCSG and any utilized Shared Resources in your publications. The level of funding we receive on this grant is determined by the science it supports, and that, in turn, is determined by acknowledging its use. You can find [citation guidelines](#) on the Cancer Consortium website.

Recommended language: *This research was supported by the [insert name] Shared Resource of the Fred Hutch/University of Washington Cancer Consortium (P30 CA015704).*

## JUNIOR FACULTY CAREER DEVELOPMENT SERIES



ITHS is offering a Career Development Series of monthly lectures and workshops designed to provide junior faculty and investigators with tools and opportunities to help advance their careers. Visit the [ITHS Career Development Series website](#) for more information and to register.

## SAVE THE DATE: BRIDGE TO GRADUATE PROGRAMS FORUM



The Office of Education & Training is hosting this forum is to connect pre-baccalaureate programs and graduate programs throughout the Consortium Institutions on **Wednesday, October 16, 2019**. Join us by RSVP'ing here: [Cancer Consortium Bridge to Graduate Programs Forum](#)

## Program Retreats

It's program retreat season! Please submit your planned retreat dates by **December 31, 2019.**

## WHY WE NEED GOOD MENTORING by DR. JULIE OVERBAUGH



Dr. Julie Overbaugh, Associate Director of Cancer Research Career Enhancement, shares her view on good, scientific mentoring in this [Nature Reviews Viewpoint article](#).

## UPDATES FROM OFFICE OF COMMUNITY OUTREACH & ENGAGEMENT (OCOE)



### Meet CECE!

The OCOE held a contest to name their new inflatable colon, and the winner is . . . CECE (which stands for Colorectal Education Cancer Exhibit)! See more [here](#).



### An Active Summer for OCOE

The Community Health Education Team was busy over the summer months. Staff participated in **18** community health fairs and events between May and August and reached over **1,100 people** in the catchment area at these events!



### Community Action Coalition Launches

Comprised of stakeholders representing organizations and communities from across our 13-county catchment area, the Coalition will work with the OCOE to support community change and positive health outcomes by providing input into decision-making for interventions, advocacy, and programs.

## NCI'S CLINICAL TRIALS REPORTING PROGRAM (CTRP) UPDATES

The NCI recently announced **changes to reporting requirements for *observational\** studies. Effective immediately**, our Center will be required to register and report IRB review dates and accrual for all observational trials that have been open to enrollment on or after January 1, 2018. NCI reporting requirements for observational studies will now be identical to interventional trial reporting requirements.

This means if you are the PI of an observational study, the NCI will require submission of all IRB-approved protocol documents and accrual information throughout the life of the study. Clinical Research Support (CRS) will be implementing new processes to meet these increased requirements. The Consortium is currently assessing the impact and identifying the best methods for retrieving trial documents and accrual information to meet this mandate by the **October 1, 2020 deadline**. Please stay tuned for additional communication and outreach from CRS.

*\*NCI defines observational trials as studies that focus on cancer patients and healthy populations and involve no prospective intervention or alteration in the status of the participants. Biomedical and/or health outcome(s) are assessed in pre-defined groups of participants. The participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator of the observational study is not responsible for assigning specific interventions to the participants of the study.*